Andere talen Revive Therapeutics Ltd.

Aandelen

RVV

CA7615161030

Beurs gesloten - Canadian Securities Exchange Andere beurzen 19:23:32 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,03 ^CAD	+20,00%		0,00%	0,00%

18/04	Revive Therapeutics Ltd. Kondigt FDA Aanvaarding van Vergaderingsverzoek voor Long COVID Diagnostic Product aan	CI
02/04	Revive Therapeutics Ltd. Geeft een update over de klinische studie naar psilocybine voor methamphetaminegebruiksstoornis	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

FDA Grants Revive Therapeutics Type C Meeting Request For Bucillamine Study to Treat Long COVID	23/04
Revive Therapeutics Brief: Announcing Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID	23/04
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID	23/04
Revive Therapeutics Announced FDA Acceptance of Meeting Request for Long COVID Diagnostic Product	18/04
Revive Therapeutics Brief: Announcing FDA Acceptance of Meeting Request for Long COVID Diagnostic Product	18/04
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product	18/04
Revive Therapeutics Ltd. Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product	18/04
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder	02/04
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder	02/04
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder	02/04
Revive Therapeutics Ltd. Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder	02/04
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID	27/03
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID	27/03
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID	27/03
Revive Therapeutics : Document	20/03
Revive Therapeutics : Document	20/03
Revive Therapeutics to Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID	19/03
Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID	19/03
Revive Therapeutics Ltd. Announces to Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID	19/03
Revive Therapeutics Provides Corporate Update	12/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Revive Therapeutics Ltd.

Aandelen

RVV

CA7615161030

Andere talen

Filters